KMI169
Product Specifications
UNSPSC Description
KMI169 is a potent and selective bi-substrate inhibitor targeting the SAM and substrate binding pockets of KMT9. KMT9 monomethylates histone H4 lysine 12 and controls the proliferation of prostate cancer cells. KMI169 can be used for the research of prostate cancer[1].
Target Antigen
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/kmi169.html
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
NC1=C2C(C3=NN(C=C3Cl)CC4=CC=CC=C4)=CN([C@@H]5C[C@H](C6=CC(CN7CCC7)=CC=C6)[C@@H](O)[C@H]5O)C2=NC(Cl)=N1
Molecular Weight
604.53
References & Citations
[1]Wang S, et al. Structure-guided design of a selective inhibitor of the methyltransferase KMT9 with cellular activity. Nat Commun. 2024 Jan 2;15(1):43.|[2]Eric Metzger, et al. KMT9 monomethylates histone H4 lysine 12 and controls proliferation of prostate cancer cells. Nature Structural & Molecular Biology. 2019
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-157486/KMI169-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-157486/KMI169-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
